Humana Inc.’s HUM business, CenterWell Senior Primary Care, opened its 250th senior primary care facility. The business is a part of HUM’s Primary Care Organization. The latest center was opened in Dallas, TX, named CenterWell Redbird.
The move marks Humana’s continuous growth in the provider space. Its CenterWell brand is expected to open 30-50 additional facilities per annum through 2025. It currently owns centers in 12 states. Humana’s Primary Care Organization also includes the Conviva Care Center brand and caters to almost 266,000 seniors across these states.
HUM’s CenterWell business focuses on providing a better healthcare experience through clubbing primary care, home health and pharmacy services. It increases efficiency and boosts affordability for users. The new center commenced seeing patients in April. The CenterWell Redbird is one of ten facilities opening this year in the Dallas Fort Worth Metroplex.
Humana is not only expanding its business geographically but also enhancing its capabilities to improve its value-based services. This is likely to result in better patient outcomes. Both its Conviva Care Center and CenterWell Senior Primary Care brands accept users from many Medicare Advantage plans and some users with Original Medicare plans.
The CenterWell segment’s revenues for 2023 are expected within $18-$18.5 billion, the mid-point of which suggests 5.5% growth from the 2022 level. The segment continues to benefit from the improving membership growth within the company’s individual Medicare Advantage business.
Humana’s shares have gained 13.6% in the past year compared with the 1.9% rise of the industry it belongs to.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
The company currently has a Zacks Rank #3 (Hold). Investors interested in the broader medical space may look at better-ranked players like Medpace Holdings, Inc. MEDP, GeneDx Holdings Corp. WGS and Establishment Labs Holdings Inc. ESTA, all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Medpace’s 2023 earnings is pegged at $8.11 per share, indicating an 11.4% improvement from the year-ago level. Also, the consensus estimate for MEDP’s revenues in 2023 suggests a 20.9% year-over-year rise.
The consensus estimate for GeneDx’s 2023 earnings indicates 89% year-over-year growth. The Zacks Consensus Estimate for WGS’ revenues in 2023 is pegged at $205 million.
The consensus mark for Establishment Labs’ 2023 earnings has improved 6.2% in the past 30 days. Furthermore, the consensus estimate for ESTA’s revenues in 2023 suggests 27.6% year-over-year growth.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report